A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to manufacturers whose sales fell sharply last year.

The Advisory Committee on Immunization Practices recommended that adults age 50 to 59 who are at high risk of severe respiratory syncytial virus get a single dose of the vaccine. RSV usually causes mild, cold-like symptoms, but can be dangerous to older adults with weakened immune systems.